Spero Therapeutics Revenue and Competitors

Boston, MA USA

Location

$434.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Spero Therapeutics's estimated annual revenue is currently $17.4M per year.(i)
  • Spero Therapeutics's estimated revenue per employee is $272,188
  • Spero Therapeutics's total funding is $434.6M.
  • Spero Therapeutics's current valuation is $426.7M. (January 2022)

Employee Data

  • Spero Therapeutics has 64 Employees.(i)
  • Spero Therapeutics grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Spero Therapeutics aims to be the premier company developing novel therapies to treat highly resistant bacterial infections. The culture at Spero is one of respect, action, collaboration and transparency. Spero team members are leaders in the field, and have the ability and desire to be a part of a team. At Spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.

keywords:N/A

$434.6M

Total Funding

64

Number of Employees

$17.4M

Revenue (est)

7%

Employee Growth %

$426.7M

Valuation

N/A

Accelerator

Spero Therapeutics News

2022-04-17 - Spero Therapeutics to Present Data at the 32nd European ...

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced two oral presentations and four...

2022-03-30 - Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase ...

CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England...

2022-03-22 - Spero Therapeutics Announces Fourth Quarter and Full Year ...

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...

2021-11-11 - Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update - Form 8-K

Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update Submitted NDA to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections, including pyelonephritis Entered into a non-dilutive revenue interest financing agreement with ...

2021-07-05 - Spero Therapeutics : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

CAMBRIDGE, Mass. - Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced that on J ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A642%N/A
#2
$21.2M64-36%$85M
#3
$18.6M642%N/A
#4
$8.1M64-11%$55.9M
#5
$10.4M6478%N/A